Skip to content
value.today

Vergent Bioscience, Inc.

🇺🇸 Minneapolis, Minnesota, USABiotechnologyFounded 2013

Formerly In Vivo Technologies, LLC, Intracellular Technologies, LLC, In Vivo Tracer Technologies, LLC

Total raised
$57 M
5 rounds on record
Latest round
$19 M
Oct 2025
First round on record
May 2018
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vergent Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$19 MNo. 5$10 to $50 million

Vergent Bioscience, Inc.: Raise no. 5, Oct 2025

Investors in this round

20 investors had bought by the notice of Oct 20, 2025: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $32 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey T. Yurecko · Executive Officer
  • John T. Santini, Jr. · Executive Officer, Director
  • Anita T. Watkins · Director
  • Bobby T. Helmedag · Director
  • Douglas T. Kohrs · Director
  • Raymond T. Wong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amounts include securities issued upon conversion of outstanding promissory notes and warrants authorized for issuance in connection with the offering.”

Signed by John T. Santini, Jr., President. Source: SEC Form D, newest notice filed Oct 20, 2025. Read the notice at the SEC.

equity, optionsSEC
Feb 2025$4 MNo. 4$2 to $10 million

Vergent Bioscience, Inc.: Raise no. 4, Feb 2025

Investors in this round

5 investors had bought by the notice of Feb 18, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Yurecko · Executive Officer
  • John Santini · Executive Officer, Director
  • Anita Wilson · Director · Ms. Wilson was elected as a Director on the Date of First Sale.
  • Bobby Helmedag · Director
  • Douglas Kohrs · Director
  • Jeff Julkowski · Director · Mr. Julkowski was a Director on the date the board approved the offering. He resigned as a Director on the Date of First
  • Raymond Wong · Director
  • Ryan Egeland · Director · Mr. Egeland was a Director on the date the board approved the offering. He resigned as a Director on the Date of First S
  • Samuel Dean Banks · Director · Mr. Dean Banks was a Director on the date the board approved the offering. He resigned as a Director on the Date of Firs

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John T. Santini, Jr., President. Source: SEC Form D and 1 amendment, newest notice filed Feb 18, 2025. Read the notice at the SEC.

debt, optionsSEC
Aug 2022$22 MNo. 3$10 to $50 million

Vergent Bioscience, Inc.: Raise no. 3, Aug 2022

Investors in this round

27 investors had bought by the notice of Oct 4, 2022: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $22 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Yurecko · Executive Officer
  • John Santini · Executive Officer, Director
  • Douglas Kohrs · Director
  • Jeffrey Julkowski · Director, Promoter
  • Margo Shoup · Director
  • Raymond Wong · Director
  • Ryan Egeland · Director
  • Samuel Banks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Santini, President. Source: SEC Form D, newest notice filed Oct 4, 2022. Read the notice at the SEC.

equitySEC
Nov 2021$1 MNo. 2Under $2 million

Vergent Bioscience, Inc.: Raise no. 2, Nov 2021

Investors in this round

16 investors had bought by the notice of Nov 22, 2021: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Dean Yurecko · Executive Officer
  • John Santini · Executive Officer, Director
  • Douglas Dean Kohrs · Director
  • Jeffrey Julkowski · Director, Promoter
  • Raymond Dean Wong · Director
  • Ryan Dean Egeland · Director
  • Samuel Dean Banks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John T. Santini, Jr., President. Source: SEC Form D, newest notice filed Nov 22, 2021. Read the notice at the SEC.

debt, optionsSEC
May 2018$12 MNo. 1$10 to $50 million

Vergent Bioscience, Inc.: Raise no. 1, May 2018

Investors in this round

21 investors had bought by the notice of Sep 23, 2020: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Dean Yurecko · Executive Officer
  • John Santini · Executive Officer, Director
  • Douglas Dean Kohrs · Director
  • Jeffrey Julkowski · Director, Promoter
  • Raymond Dean Wong · Director
  • Ryan Dean Egeland · Director
  • Samuel Dean Banks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John T. Santini, Jr., President. Source: SEC Form D and 2 amendments, newest notice filed Sep 23, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vergent Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2025).

    SEC Form D · Oct 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2025

That is all the official record says: Vergent Bioscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vergent Bioscience, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 27 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vergent Bioscience, Inc.
NameRoleNamed in
Jeffrey T. YureckoExecutive officerOct 2025
John T. Santini, Jr.Executive officerOct 2025
Jeffrey YureckoExecutive officerFeb 2025
John SantiniExecutive officerFeb 2025
Jeffrey Dean YureckoExecutive officerNov 2021
Anita T. WatkinsDirectorOct 2025
Bobby T. HelmedagDirectorOct 2025
Douglas T. KohrsDirectorOct 2025
John T. Santini, Jr.DirectorOct 2025
Raymond T. WongDirectorOct 2025
Anita WatkinsMs. Wilson was elected as a Director on the Date of First Sale.Feb 2025
Anita WilsonMs. Wilson was elected as a Director on the Date of First Sale.Feb 2025
Bobby HelmedagDirectorFeb 2025
Douglas KohrsDirectorFeb 2025
Jeff JulkowskiMr. Julkowski was a Director on the date the board approved the offering. He resigned as a Director on the Date of FirstFeb 2025
John SantiniDirectorFeb 2025
Raymond WongDirectorFeb 2025
Ryan EgelandMr. Egeland was a Director on the date the board approved the offering. He resigned as a Director on the Date of First SFeb 2025
Samuel Dean BanksMr. Dean Banks was a Director on the date the board approved the offering. He resigned as a Director on the Date of FirsFeb 2025
Jeffrey JulkowskiDirectorOct 2022
Margo ShoupDirectorOct 2022
Samuel BanksDirectorOct 2022
Douglas Dean KohrsDirectorNov 2021
Raymond Dean WongDirectorNov 2021
Ryan Dean EgelandDirectorNov 2021
Jeffrey JulkowskiPromoterOct 2022